Asabys Partners, a specialist in early-stage biotech, medical technology and healthcare innovation projects, led a €14m Series A round in Gradient Denervation Technologies, a developer of a medical device for a transvascular treatment of pulmonary hypertension, with participation from Thuja Capital and Sofinnova Partners. “I’m very happy to welcome Asabys Partners and Thuja Capital to the Gradient team. In addition to capital, these investors bring deep expertise and thought partnership to Gradient as we seek to bring our technology to patients,” Martin Grasse, Gradient CEO.